| CereVasc, Inc. Completes Enrollment in STRIDE Pivotal Trial of the eShunt® System Advancing Toward FDA Premarket Approval (PMA) for a Minimally Invasive Treatment of Normal Pressure Hydrocephalus STRIDE is the first and largest randomized, controlled trial conducted comparing a minimally invasive alternative to the standard-of-care ventriculo-peritoneal (VP) shunt, a treatment paradigm largely unchanged in […] The post CereVasc, Inc. Completes Enrollment in STRIDE Pivotal Trial of the eShunt® System appeared first on CereVasc |
Neurological Disease Device Company . |
